{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:20:28Z","timestamp":1792516828798,"version":"4.5.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We evaluated immune cell subsets in patients with chronic lymphocytic leukemia (CLL) who received first-line therapy with 3 cycles of ibrutinib then 13 cycles of ibrutinib plus venetoclax in the minimal residual disease (MRD) cohort of the CAPTIVATE study (NCT02910583). Patients with Confirmed undetectable MRD (uMRD) were randomly assigned to placebo or ibrutinib groups; patients without Confirmed uMRD were randomly assigned to ibrutinib or ibrutinib plus venetoclax groups. We compared immune cell subsets in samples collected at 7 time points with age-matched healthy donors. CLL cells decreased within 3 cycles after venetoclax initiation; from cycle 16 onward, levels were similar to healthy donor levels (HDL; \u22640.8 cells per \u03bcL) in patients with Confirmed uMRD and slightly above HDL in patients without Confirmed uMRD. By 4\u00a0months after cycle 16, normal B cells had recovered to HDL in patients randomly assigned to placebo. Regardless of randomized treatment, abnormal counts of T\u00a0cells, classical monocytes, and conventional dendritic cells recovered to HDL within 6\u00a0months (median change from baseline \u221249%,\u00a0+101%, and\u00a0+91%, respectively); plasmacytoid dendritic cells recovered by cycle 20 (+598%). Infections generally decreased over time regardless of randomized treatment and were numerically lowest in patients randomly assigned to placebo within 12\u00a0months after cycle 16. Sustained elimination of CLL cells and recovery of normal B cells were confirmed in samples from patients treated with fixed-duration ibrutinib plus venetoclax in the GLOW study (NCT03462719). These results demonstrate promising evidence of restoration of normal blood immune composition with ibrutinib plus venetoclax.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010236","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T19:32:58Z","timestamp":1686771178000},"page":"5294-5303","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study"],"prefix":"10.1182","volume":"7","author":[{"given":"Carol","family":"Moreno","sequence":"first","affiliation":[{"name":"1Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Leukaemia Research Institute, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle G.","family":"Solman","sequence":"additional","affiliation":[{"name":"2Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Alfred Hospital and Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Grigg","sequence":"additional","affiliation":[{"name":"4Austin Hospital, Heidelberg, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-0989","authenticated-orcid":false,"given":"Lydia","family":"Scarf\u00f2","sequence":"additional","affiliation":[{"name":"5Division of Experimental Oncology, Universit\u00e0 Vita Salute San Raffaele and Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0064-4549","authenticated-orcid":false,"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"6Moores Cancer Center, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srimathi","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"7Janssen Research & Development, Lower Gwynedd Township, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghuveer Singh","family":"Mali","sequence":"additional","affiliation":[{"name":"2Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Zhou","sequence":"additional","affiliation":[{"name":"2Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Dean","sequence":"additional","affiliation":[{"name":"2Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Szafer-Glusman","sequence":"additional","affiliation":[{"name":"2Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Choi","sequence":"additional","affiliation":[{"name":"8University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"issue":"34","key":"2023092213345489100_bib1","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"2023092213345489100_bib2","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2023092213345489100_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"16","key":"2023092213345489100_bib4","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2023092213345489100_bib5","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"2023092213345489100_bib6","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2023092213345489100_bib7","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"2023092213345489100_bib8","doi-asserted-by":"crossref","first-page":"106432","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leuk Res"},{"key":"2023092213345489100_bib9","doi-asserted-by":"crossref","first-page":"106520","DOI":"10.1016\/j.leukres.2021.106520","article-title":"Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia","volume":"102","author":"Solman","year":"2021","journal-title":"Leuk Res"},{"issue":"3","key":"2023092213345489100_bib10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.seminhematol.2014.05.006","article-title":"Immunomodulation and immune reconstitution in chronic lymphocytic leukemia","volume":"51","author":"Riches","year":"2014","journal-title":"Semin Hematol"},{"issue":"5","key":"2023092213345489100_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2023092213345489100_bib12","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.V62.6.1289.1289","article-title":"Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia","volume":"62","author":"Pizzolo","year":"1983","journal-title":"Blood"},{"issue":"3","key":"2023092213345489100_bib13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/1097-0320(20000615)42:3<188::AID-CYTO5>3.0.CO;2-Q","article-title":"Expansions of clonal and oligoclonal T cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3(+)CD8(+) T-cell population","volume":"42","author":"Goolsby","year":"2000","journal-title":"Cytometry"},{"issue":"2","key":"2023092213345489100_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0145-2126(97)00152-5","article-title":"Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment","volume":"22","author":"Van den Hove","year":"1998","journal-title":"Leuk Res"},{"issue":"9","key":"2023092213345489100_bib15","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T\u00a0cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2023092213345489100_bib16","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1172\/JCI24176","article-title":"Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8\u00a0T cells","volume":"115","author":"G\u00f6rg\u00fcn","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"2023092213345489100_bib17","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"2023092213345489100_bib18","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2023092213345489100_bib19","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","article-title":"CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2023092213345489100_bib20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/10428194.2017.1330475","article-title":"Regulatory T-cells drive immune dysfunction in CLL","volume":"59","author":"Lad","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"2023092213345489100_bib21","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2023092213345489100_bib22","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"2023092213345489100_bib23","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.4049\/jimmunol.1601190","article-title":"Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia","volume":"198","author":"Yin","year":"2017","journal-title":"J\u00a0Immunol"},{"issue":"18","key":"2023092213345489100_bib24","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1158\/1078-0432.CCR-19-3827","article-title":"T-cell dynamics in chronic lymphocytic leukemia under different treatment modalities","volume":"26","author":"Vardi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2023092213345489100_bib25","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2023092213345489100_bib26","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"key":"2023092213345489100_bib27","doi-asserted-by":"crossref","first-page":"833714","DOI":"10.3389\/fonc.2022.833714","article-title":"Targeting Mcl-1 by AMG-176 during ibrutinib and venetoclax therapy in chronic lymphocytic leukemia","volume":"12","author":"Yi","year":"2022","journal-title":"Front Oncol"},{"key":"2023092213345489100_bib28","first-page":"3018","article-title":"Combinatorial treatment of chronic lymphocytic leukemia with ibrutinib and venetoclax is superior to treatment with single agents in the TCL1 mouse model","volume":"130","author":"Slinger","year":"2017","journal-title":"Blood"},{"issue":"23","key":"2023092213345489100_bib29","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1182\/bloodadvances.2021004861","article-title":"Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia","volume":"5","author":"Kater","year":"2021","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/18\/5294\/2079835\/blooda_adv-2023-010236-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/18\/5294\/2079835\/blooda_adv-2023-010236-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T13:35:15Z","timestamp":1695389715000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/18\/5294\/496294\/Immune-restoration-with-ibrutinib-plus-venetoclax"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":29,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,9,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010236","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]}}}